Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash & Equivalents (2022 - 2025)

NewAmsterdam Pharma's Cash & Equivalents history spans 4 years, with the latest figure at $490.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 36.51% year-over-year to $490.0 million; the TTM value through Dec 2025 reached $490.0 million, down 36.51%, while the annual FY2025 figure was $490.0 million, 36.51% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $490.0 million at NewAmsterdam Pharma, down from $538.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $771.7 million in Q4 2024 and bottomed at $340.4 million in Q4 2023.
  • The 4-year median for Cash & Equivalents is $447.4 million (2022), against an average of $497.0 million.
  • The largest annual shift saw Cash & Equivalents surged 126.68% in 2024 before it tumbled 36.51% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $447.4 million in 2022, then fell by 23.9% to $340.4 million in 2023, then soared by 126.68% to $771.7 million in 2024, then plummeted by 36.51% to $490.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Cash & Equivalents are $490.0 million (Q4 2025), $538.4 million (Q3 2025), and $563.9 million (Q2 2025).